Radioligand Therapy Market Report 2026

Radioligand Therapy Market Overview

• Radioligand Therapy market size has reached to $6.63 billion in 2025 • Expected to grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies • Market Trend: Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Radioligand Therapy Market?

Radioligand therapy (RLT) is an advanced form of targeted cancer treatment that links a radioactive isotope to a ligand designed to bind selectively to cancer cell receptors. After administration, it seeks out tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissue. Its targeted approach helps reduce side effects and improves outcomes, particularly in cases resistant to traditional treatments. The main types of radioligands in radioligand therapy are alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, just a few cell layers, making them highly effective for targeted cell destruction. These radioligands are designed to bind to specific molecular targets such as hormone receptors, growth factor receptors, antigen tumor markers, and others and can be administered through various routes of administration, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a range of conditions such as oncological and cardiovascular disorders, neurological disorders, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care setting.

What Is The Radioligand Therapy Market Growth Forecast?

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

Global Radioligand Therapy Market Segmentation

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions 2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets 3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral 4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases 5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings Subsegments: 1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213) 2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153) 3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201) 4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Is The Driver Of The Radioligand Therapy Market?

The increasing cancer incidence is expected to propel the growth of the radioligand therapy market going forward. Cancer is a disease marked by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. Cancer incidence is rising due to long-term exposure to environmental pollutants that damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increasing cancer incidence is driving the growth of the radioligand therapy industry.

Key Players In The Global Radioligand Therapy Market

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.

Global Radioligand Therapy Market Trends and Insights

Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

What Are Latest Mergers And Acquisitions In The Radioligand Therapy Market?

In December 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired POINT Biopharma Global Inc. for $1.4 billion. With this acquisition, Eli Lilly and Company aims to expand its oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment offerings. POINT Biopharma Global Inc. is a US-based pharmaceutical company that specializes in the development of radioligand treatments for cancer.

Regional Insights

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radioligand Therapy Market?

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Radioligand Therapy Market Report 2026?

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.